The global Vildagliptin Tablets market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Vildagliptin Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Vildagliptin Tablets is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Vildagliptin Tablets include Novartis Farmaceutica SA., Siegfried Barbera S.L., Takeda, Merck, Daiichi Sankyo, Yangtze River Pharmaceutical (Group) Co., Ltd., Hybio Pharmaceutical Co., Ltd., KP Pharmacy Co., Ltd. and Jiangsu Desano Pharmaceutical Co., Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Vildagliptin Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vildagliptin Tablets.
Report Scope
The Vildagliptin Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vildagliptin Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vildagliptin Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Novartis Farmaceutica SA.
Siegfried Barbera S.L.
Takeda
Merck
Daiichi Sankyo
Yangtze River Pharmaceutical (Group) Co., Ltd.
Hybio Pharmaceutical Co., Ltd.
KP Pharmacy Co., Ltd.
Jiangsu Desano Pharmaceutical Co., Ltd.
Nanjing Sanhome Pharmaceutical Co.Ltd.,
QILU Pharmaceutical Co., Ltd.
Nanjing YOKO Pharmaceutical Co., Ltd.
Hefei Yingtai Pharmaceutical Co., Ltd.
Hainan General Sanyang Pharmaceutical Co., Ltd.
Hansoh Pharmaceutical Group Company Limited
Yantai Wanrun Pharmaceutical Co., Ltd.
China Resources SAIKE Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Shandong YUXIN Pharmaceutical Co., Ltd.
Segment by Type
Ordinary Vildagliptin Tablets
Metformin Hydrochloride and Vildagliptin Tablets
Segment by Application
Hospital
Clinic
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vildagliptin Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vildagliptin Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Vildagliptin Tablets 麻豆原创 Overview
1.1 Product Overview and Scope of Vildagliptin Tablets
1.2 Vildagliptin Tablets Segment by Type
1.2.1 Global Vildagliptin Tablets 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Ordinary Vildagliptin Tablets
1.2.3 Metformin Hydrochloride and Vildagliptin Tablets
1.3 Vildagliptin Tablets Segment by Application
1.3.1 Global Vildagliptin Tablets 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Retail Pharmacy
1.3.5 Others
1.4 Global Vildagliptin Tablets 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Vildagliptin Tablets Revenue 2019-2030
1.4.2 Global Vildagliptin Tablets Sales 2019-2030
1.4.3 Global Vildagliptin Tablets 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Vildagliptin Tablets 麻豆原创 Competition by Manufacturers
2.1 Global Vildagliptin Tablets Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Vildagliptin Tablets Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Vildagliptin Tablets Average Price by Manufacturers (2019-2024)
2.4 Global Vildagliptin Tablets Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vildagliptin Tablets, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vildagliptin Tablets, Product Type & Application
2.7 Vildagliptin Tablets 麻豆原创 Competitive Situation and Trends
2.7.1 Vildagliptin Tablets 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Vildagliptin Tablets Players 麻豆原创 Share by Revenue
2.7.3 Global Vildagliptin Tablets 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Vildagliptin Tablets Retrospective 麻豆原创 Scenario by Region
3.1 Global Vildagliptin Tablets 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Vildagliptin Tablets Global Vildagliptin Tablets Sales by Region: 2019-2030
3.2.1 Global Vildagliptin Tablets Sales by Region: 2019-2024
3.2.2 Global Vildagliptin Tablets Sales by Region: 2025-2030
3.3 Global Vildagliptin Tablets Global Vildagliptin Tablets Revenue by Region: 2019-2030
3.3.1 Global Vildagliptin Tablets Revenue by Region: 2019-2024
3.3.2 Global Vildagliptin Tablets Revenue by Region: 2025-2030
3.4 North America Vildagliptin Tablets 麻豆原创 Facts & Figures by Country
3.4.1 North America Vildagliptin Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Vildagliptin Tablets Sales by Country (2019-2030)
3.4.3 North America Vildagliptin Tablets Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Vildagliptin Tablets 麻豆原创 Facts & Figures by Country
3.5.1 Europe Vildagliptin Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Vildagliptin Tablets Sales by Country (2019-2030)
3.5.3 Europe Vildagliptin Tablets Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vildagliptin Tablets 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Vildagliptin Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Vildagliptin Tablets Sales by Country (2019-2030)
3.6.3 Asia Pacific Vildagliptin Tablets Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Vildagliptin Tablets 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Vildagliptin Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Vildagliptin Tablets Sales by Country (2019-2030)
3.7.3 Latin America Vildagliptin Tablets Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vildagliptin Tablets 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Vildagliptin Tablets 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Vildagliptin Tablets Sales by Country (2019-2030)
3.8.3 Middle East and Africa Vildagliptin Tablets Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vildagliptin Tablets Sales by Type (2019-2030)
4.1.1 Global Vildagliptin Tablets Sales by Type (2019-2024)
4.1.2 Global Vildagliptin Tablets Sales by Type (2025-2030)
4.1.3 Global Vildagliptin Tablets Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Vildagliptin Tablets Revenue by Type (2019-2030)
4.2.1 Global Vildagliptin Tablets Revenue by Type (2019-2024)
4.2.2 Global Vildagliptin Tablets Revenue by Type (2025-2030)
4.2.3 Global Vildagliptin Tablets Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Vildagliptin Tablets Price by Type (2019-2030)
5 Segment by Application
5.1 Global Vildagliptin Tablets Sales by Application (2019-2030)
5.1.1 Global Vildagliptin Tablets Sales by Application (2019-2024)
5.1.2 Global Vildagliptin Tablets Sales by Application (2025-2030)
5.1.3 Global Vildagliptin Tablets Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Vildagliptin Tablets Revenue by Application (2019-2030)
5.2.1 Global Vildagliptin Tablets Revenue by Application (2019-2024)
5.2.2 Global Vildagliptin Tablets Revenue by Application (2025-2030)
5.2.3 Global Vildagliptin Tablets Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Vildagliptin Tablets Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis Farmaceutica SA.
6.1.1 Novartis Farmaceutica SA. Corporation Information
6.1.2 Novartis Farmaceutica SA. Description and Business Overview
6.1.3 Novartis Farmaceutica SA. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Farmaceutica SA. Vildagliptin Tablets Product Portfolio
6.1.5 Novartis Farmaceutica SA. Recent Developments/Updates
6.2 Siegfried Barbera S.L.
6.2.1 Siegfried Barbera S.L. Corporation Information
6.2.2 Siegfried Barbera S.L. Description and Business Overview
6.2.3 Siegfried Barbera S.L. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Siegfried Barbera S.L. Vildagliptin Tablets Product Portfolio
6.2.5 Siegfried Barbera S.L. Recent Developments/Updates
6.3 Takeda
6.3.1 Takeda Corporation Information
6.3.2 Takeda Description and Business Overview
6.3.3 Takeda Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takeda Vildagliptin Tablets Product Portfolio
6.3.5 Takeda Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Vildagliptin Tablets Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Daiichi Sankyo Vildagliptin Tablets Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
6.6 Yangtze River Pharmaceutical (Group) Co., Ltd.
6.6.1 Yangtze River Pharmaceutical (Group) Co., Ltd. Corporation Information
6.6.2 Yangtze River Pharmaceutical (Group) Co., Ltd. Description and Business Overview
6.6.3 Yangtze River Pharmaceutical (Group) Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Yangtze River Pharmaceutical (Group) Co., Ltd. Vildagliptin Tablets Product Portfolio
6.6.5 Yangtze River Pharmaceutical (Group) Co., Ltd. Recent Developments/Updates
6.7 Hybio Pharmaceutical Co., Ltd.
6.6.1 Hybio Pharmaceutical Co., Ltd. Corporation Information
6.6.2 Hybio Pharmaceutical Co., Ltd. Description and Business Overview
6.6.3 Hybio Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hybio Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.7.5 Hybio Pharmaceutical Co., Ltd. Recent Developments/Updates
6.8 KP Pharmacy Co., Ltd.
6.8.1 KP Pharmacy Co., Ltd. Corporation Information
6.8.2 KP Pharmacy Co., Ltd. Description and Business Overview
6.8.3 KP Pharmacy Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.8.4 KP Pharmacy Co., Ltd. Vildagliptin Tablets Product Portfolio
6.8.5 KP Pharmacy Co., Ltd. Recent Developments/Updates
6.9 Jiangsu Desano Pharmaceutical Co., Ltd.
6.9.1 Jiangsu Desano Pharmaceutical Co., Ltd. Corporation Information
6.9.2 Jiangsu Desano Pharmaceutical Co., Ltd. Description and Business Overview
6.9.3 Jiangsu Desano Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Jiangsu Desano Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.9.5 Jiangsu Desano Pharmaceutical Co., Ltd. Recent Developments/Updates
6.10 Nanjing Sanhome Pharmaceutical Co.Ltd.,
6.10.1 Nanjing Sanhome Pharmaceutical Co.Ltd., Corporation Information
6.10.2 Nanjing Sanhome Pharmaceutical Co.Ltd., Description and Business Overview
6.10.3 Nanjing Sanhome Pharmaceutical Co.Ltd., Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Nanjing Sanhome Pharmaceutical Co.Ltd., Vildagliptin Tablets Product Portfolio
6.10.5 Nanjing Sanhome Pharmaceutical Co.Ltd., Recent Developments/Updates
6.11 QILU Pharmaceutical Co., Ltd.
6.11.1 QILU Pharmaceutical Co., Ltd. Corporation Information
6.11.2 QILU Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.11.3 QILU Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.11.4 QILU Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.11.5 QILU Pharmaceutical Co., Ltd. Recent Developments/Updates
6.12 Nanjing YOKO Pharmaceutical Co., Ltd.
6.12.1 Nanjing YOKO Pharmaceutical Co., Ltd. Corporation Information
6.12.2 Nanjing YOKO Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.12.3 Nanjing YOKO Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Nanjing YOKO Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.12.5 Nanjing YOKO Pharmaceutical Co., Ltd. Recent Developments/Updates
6.13 Hefei Yingtai Pharmaceutical Co., Ltd.
6.13.1 Hefei Yingtai Pharmaceutical Co., Ltd. Corporation Information
6.13.2 Hefei Yingtai Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.13.3 Hefei Yingtai Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Hefei Yingtai Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.13.5 Hefei Yingtai Pharmaceutical Co., Ltd. Recent Developments/Updates
6.14 Hainan General Sanyang Pharmaceutical Co., Ltd.
6.14.1 Hainan General Sanyang Pharmaceutical Co., Ltd. Corporation Information
6.14.2 Hainan General Sanyang Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.14.3 Hainan General Sanyang Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hainan General Sanyang Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.14.5 Hainan General Sanyang Pharmaceutical Co., Ltd. Recent Developments/Updates
6.15 Hansoh Pharmaceutical Group Company Limited
6.15.1 Hansoh Pharmaceutical Group Company Limited Corporation Information
6.15.2 Hansoh Pharmaceutical Group Company Limited Vildagliptin Tablets Description and Business Overview
6.15.3 Hansoh Pharmaceutical Group Company Limited Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Hansoh Pharmaceutical Group Company Limited Vildagliptin Tablets Product Portfolio
6.15.5 Hansoh Pharmaceutical Group Company Limited Recent Developments/Updates
6.16 Yantai Wanrun Pharmaceutical Co., Ltd.
6.16.1 Yantai Wanrun Pharmaceutical Co., Ltd. Corporation Information
6.16.2 Yantai Wanrun Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.16.3 Yantai Wanrun Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Yantai Wanrun Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.16.5 Yantai Wanrun Pharmaceutical Co., Ltd. Recent Developments/Updates
6.17 China Resources SAIKE Pharmaceutical Co., Ltd.
6.17.1 China Resources SAIKE Pharmaceutical Co., Ltd. Corporation Information
6.17.2 China Resources SAIKE Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.17.3 China Resources SAIKE Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.17.4 China Resources SAIKE Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.17.5 China Resources SAIKE Pharmaceutical Co., Ltd. Recent Developments/Updates
6.18 Shandong Langnuo Pharmaceutical Co., Ltd.
6.18.1 Shandong Langnuo Pharmaceutical Co., Ltd. Corporation Information
6.18.2 Shandong Langnuo Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.18.3 Shandong Langnuo Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Shandong Langnuo Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.18.5 Shandong Langnuo Pharmaceutical Co., Ltd. Recent Developments/Updates
6.19 Shandong YUXIN Pharmaceutical Co., Ltd.
6.19.1 Shandong YUXIN Pharmaceutical Co., Ltd. Corporation Information
6.19.2 Shandong YUXIN Pharmaceutical Co., Ltd. Vildagliptin Tablets Description and Business Overview
6.19.3 Shandong YUXIN Pharmaceutical Co., Ltd. Vildagliptin Tablets Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Shandong YUXIN Pharmaceutical Co., Ltd. Vildagliptin Tablets Product Portfolio
6.19.5 Shandong YUXIN Pharmaceutical Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vildagliptin Tablets Industry Chain Analysis
7.2 Vildagliptin Tablets Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vildagliptin Tablets Production Mode & Process
7.4 Vildagliptin Tablets Sales and 麻豆原创ing
7.4.1 Vildagliptin Tablets Sales Channels
7.4.2 Vildagliptin Tablets Distributors
7.5 Vildagliptin Tablets Customers
8 Vildagliptin Tablets 麻豆原创 Dynamics
8.1 Vildagliptin Tablets Industry Trends
8.2 Vildagliptin Tablets 麻豆原创 Drivers
8.3 Vildagliptin Tablets 麻豆原创 Challenges
8.4 Vildagliptin Tablets 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Novartis Farmaceutica SA.
Siegfried Barbera S.L.
Takeda
Merck
Daiichi Sankyo
Yangtze River Pharmaceutical (Group) Co., Ltd.
Hybio Pharmaceutical Co., Ltd.
KP Pharmacy Co., Ltd.
Jiangsu Desano Pharmaceutical Co., Ltd.
Nanjing Sanhome Pharmaceutical Co.Ltd.,
QILU Pharmaceutical Co., Ltd.
Nanjing YOKO Pharmaceutical Co., Ltd.
Hefei Yingtai Pharmaceutical Co., Ltd.
Hainan General Sanyang Pharmaceutical Co., Ltd.
Hansoh Pharmaceutical Group Company Limited
Yantai Wanrun Pharmaceutical Co., Ltd.
China Resources SAIKE Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Shandong YUXIN Pharmaceutical Co., Ltd.
听
听
*If Applicable.